Amendments to the Claims:

Listing of Claims:

Claim 1 (original): Microparticles comprising a somatostatin analogue comprising the amino acid sequence of formula I

-(D/L)Trp-LYs-X_1 -X_2 - I

wherein X_1 is a radical of formula (a) or (b)



(a)



(b)

wherein R_1 is optionally substituted phenyl,

R_2 is $-Z_1-CH_2-R_1$, $-CH_2-CO-O-CH_2-R_1$,



or



wherein Z_1 is O or S, and

X_2 is an α-amino acid having an aromatic residue on the C_α side chain, or an amino acid unit selected from Dab, Dpr, Dpm, His, (Bzl)HyPro, thienyl-Ala, cyclohexyl-Ala and t-butyl-Ala, the residue Lys of said sequence corresponding to the residue Lys^9 of the native somatostatin-14

in free form, salt form, or protected form,

embedded in a polymer matrix.

Claim 2 (original): Microparticles according to claim 1 wherein the somatostatin analogue is a compound of formula III



III

wherein the configuration at C-2 is (R) or (S) or a mixture thereof, and

wherein R is NR_1R_2-C_{2-6}alkylene or guanidine-C_{2-6}alkylene, and each of R_1 and R_2 independently is H or C_{1-4}alkyl,

in free form, salt form or protected form.

Claim 3 (currently amended): Microparticles according to claim 1 ~~or 2~~ wherein the somatostatin analogue is in pamoate salt form.

Claim 4 (currently amended): Microparticles according to ~~any preceding~~ claim 1 wherein the polymer matrix comprises a linear or branched polylactide-co-glycolide.

Claim 5 (currently amended): Microparticles according to ~~any preceding~~ claim 1 wherein the polymeric matrix comprises at least two different polymers.

Claim 6 (currently amended): Microparticles according to ~~any preceding~~ claim 1 further comprising a surfactant, a porosity influencing agent and/or a basic salt.

Claim 7 (currently amended): A pharmaceutical composition comprising microparticles of ~~any preceding~~ claim 1 and a water-based vehicle comprising a wetting agent.

Claim 8 (original): A composition according to claim 7 wherein the wetting agent comprises a poloxamer and/or a polyoxyethylene-sorbitan-fatty acid ester.

Claim 9 (currently amended): A composition according to ~~any one of claims 7 or 8~~claim 7 wherein the vehicle comprises a tonicity agent.

Claim 10 (currently amended): A composition according to ~~any one of claims 7 or 8~~claim 7 wherein the vehicle comprises a viscosity increasing agent.

Claim 11 (currently amended): A kit comprising microparticles according to ~~any one of claims 1 to 6~~claim 1 and a water-based vehicle.

Claim 12 Canceled.

Claim 13 (currently amended): A method of treating a disease or disorder with an aetiology comprising or associated with excess GH- and/or IGF-1 secretion in a subject in need thereof which comprises administering microparticles according to claim 1~~any one of claims 1 to 6 or of a pharmaceutical composition according to any one of claims 7 to 10 to the subject~~.